Archive for the ‘Clinical Trials’ Category

X-Body BioSciences and Tanabe Research Labs Team Up to Develop mAbs for Autoimmune Diseases

Last Updated on Tuesday, 4 October 2011 12:18 Written by admin Tuesday, 4 October 2011 12:18

X-Body Biosciences entered a partnership with Tanabe Research Laboratories (TRL) to identify therapeutic target epitopes and develop monospecific and/or bispecific antibodies against those targets. TRL is focussed on discovery and development of biologicals for autoimmune diseases.

Under terms of the deal, X-Body will be responsible for screening, and TRL will fund the work. TRL has the option to negotiate rights to the antibodies discovered in the collaboration for further preclinical research, clinical development, and commercialization.

X-Body will leverage its human antibody library and Protein Chain Reaction™ screening technology. The platform reportedly allows for screening against cell surface targets in their native state on live cells or purified target proteins.

This selection system employs next-generation sequencing to analyze thousands of hits to obtain high-quality leads. The modular leads generated can be incorporated into V(H) domain, scFv, IgG, and bispecific antibody formats.

“X-Body’s technology represents a major step forward in the ability to rapidly generate thousands of human antibodies against functionally relevant targets,” according to Roland Newman, Ph.D., CSO of TRL. “The power and versatility of X-Body’s platform in generating antibodies against targets that are inaccessible by conventional techniques offers new and exciting prospects.”

Source: http://www.genengnews.com/gen-news-highlights/x-body-biosciences-and-tanabe-research-labs-team-up-to-develop-mabs-for-autoimmune-diseases/81245774/

Posted under Cell Analysis, Clinical Trials, Discoveries, Innovations and Patents, Medicinal Chemistry, R & D, Reports, Research Projects | Comments Off

Scientists Use Mutant Protein to Inhibit Cancer Stem Cells and Resensitize Tumors to Lapatinib

Last Updated on Wednesday, 14 September 2011 01:56 Written by admin Wednesday, 14 September 2011 01:56

Blocking a cancer cell protein from binding to three other proteins may provide a new approach to cancer therapy that both reduces populations of breast cancer initiating cells (BCICs) in breast tumors and sensitizes the tumors to existing treatments such as lapatinib or paclitaxel, scientists claim. The technique uses a specially designed lipid-based vector to make cancer cells, including BCICs, express a mutant form of the BH3-only proapoptotic protein (Bik).

The mutant protein, called BikDD, essentially competes with Bik for binding to the three antiapoptotic proteins Bcl-2, Bcl-xL, and Mcl-1. This results in significant antitumor and apoptotic effects and, importantly, improves the anticancer effects of lapatinib or paclitaxel in relevant tumor types, claim the University of Texas M.D. Anderson Cancer Center researchers.

Reporting on their in vitro and in vivo studies in Cancer Cell, Mien-Chie Hung, Ph.D., and colleagues, claim that their results in addition highlight an important role for the antiapoptotic Bcl-2 proteins in the survival of BCICs. Their paper is titled “BikDD Eliminates Breast Cancer Initiating Cells and Synergizes with Lapatinib for Breast Cancer Treatment.”

There are currently no drugs that can effectively reduce BCICs in patients, and resistance of these cells to chemo- and radiotherapies means that following therapy, the relative proportions of these cells in the tumors increase, and eventually lead to relapse, the researchers report.

One of the key mechanisms accounting for chemoresistance in cancer-initiating cells is their low susceptibility to apoptosis, and previous lines of research have implicated the Bcl-2 family of proteins in the ability of cancer cells to escape apoptosis in response to cancer therapy. For example, studies have shown that overexpression of the antiapoptosis proteins Bcl-2, Bcl-xL, and Mcl-1 correlates with high tumor grade, poor patient prognosis, and the development of resistance to chemotherapy.

More specifically, the acquired resistance of breast cancer cells to lapatinib has been linked with overexpression of Bcl-2 and Mcl-1, suggesting that lapatinib-induced apoptosis requires inactivation of antiapoptotic Bcl-2 family proteins.

The Anderson team hypothesized that because the overall expression pattern of Bcl-2, Bcl-xL, and Mcl-1 appears to correlate inversely with apoptotic response following drug treatment, an antagonist that targets all of these antiapoptotic proteins might stand a good chance of acting to reinstate apoptotic pathways in breast cancer cells.

The researchers’ approach to achieving this involved introducing into cancer cells a competitive inhibitor, a mutant form of the Bik protein that normally binds to to Bcl-2, Bcl-xL, and Mcl-1. To test whether this approach might work, they delivered a lentivirus carrying the BIKDD gene into cells from the human breast cancer line MDA-MB-468. These tests provided confirmation that expression of BikDD significantly inhibited cell growth and resulted in large numbers of apoptotic bodies.

Interestingly, expression of BikDD also reduced the population of CD44⁺/CD24^-cells (which have previously been identified as breast cancer stem-type cells) and reduced mamosphere formation in vitro. These results were recapitulated in a different cell line: Infecting BT474 human breast cancer cells with the BikDD vector also led to a reduction in the CD44⁺/CD24^-population and of mammosphere formation. Importantly, introducing BikDD into human primary breast tumor samples that had undergone radiation therapy similarly led to significant reductions in the CD44⁺/CD24^-cell population, and mammosphere formation. Equivalent results were obtained using primary mouse tumor cells: administration of BikDD led to marked reductions in populations of mouse breast stem cells, and again blocked mammosphere formation.

The team went on to investigate whether BikDD could also inhibit cancer initiation. They infected mamospheres from MDA-MB-468 parental cells using the BikDD vector, and then injected surviving cells into NOD/SCID mice. Compared with untreated MDA-MB-468 cells, which readily formed tumors, the BikDD-infected cells demonstrated much lower cancer-forming capacity in vivo, and virtually no tumors developed in the recipient animals, suggesting that BikDD treatment reduced the BCIC population, the researchers remark.

They then adopted a gene therapy protocol that allows for the assay of cancer initiation activity in tumor xenografts growing in mice after BikDD treatment. This approach exploits a cancer cell-targeting platform developed at the MD Anderson Center, called VISA, VISA’ (VP16-GAL4-WPRE integrated systemic amplifier), which is based on an engineered, promotor-driven expression vector designed to enhance cancer-specific promoter activity by several hundred-fold, and prolong duration of gene expression without loss of cancer specificity.

Mice bearing MDA-MB-468 tumor xenografts were treated using either a control vector-liposome or with VISA-claudin4-BikDD-liposome complexes, and resulting tumor tissues removed and subsequently passaged into new animals. The results showed that transplanted cells taken from mice that had been treated with VISAclaudin4-BikDD-liposome complexes were far less tumorigenic in new animals than those from mice treated with vector-control-liposome complexes. In fact, none of the animals given tumor cells from the VISA-claudin4-BikDD-treated mice developed cancers. These animals also demonstrated lower numbers of CD44+/CD24^- cells, and fewer mammospheres formed after VISAclaudin4-BikDD treatment.

Because the team’s previous work had suggested that in comparison with wild-type Bik, BikDD demonstrates enhanced binding affinity to Bcl-2 antiapoptotic proteins, they looked more specifically at the effect of its major binding partners Bcl-2, Bcl-xL, and Mcl-1, in BCICs. Using combinations of shRNAs to silence the three Bcl-2, Bcl-xL, and Mcl-1 either individually or in combinations in cultured cells, the researchers found that while knocking down any of the proteins individually had no effect on the numbers of BCIC cells, silencing all three simultaneously reduced the CD44⁺/CD24^-population to 25% of that in control MDA-MB-468 cells, and consequently decreased mammosphere formation. Similar results were obtained using different shRNAs (to verify that the effects weren’t due to off-target activity), and in a different cell line.

“Taken together, we determined that efficient induction of apoptosis in BCICs requires silencing of all three antiapoptotic Bcl-2 proteins, which suggests that co-antagonism of multiple Bcl-2 antiapoptotic proteins by BikDD may have a better killing effect against BCICs than targeting individual antiapoptotic proteins, which is likely due to their functional redundancy in the survival of BCICs,” the authors state.

They then exploited the cancer cell-targeting VISA technology to test the therapeutic effects of BikDD gene therapy both in vitro and in vivo. To this end, they engineered a VISA vector that would express BikDD under the claudin-4 promoter that is selectively expressed in breast cancer cells. Testing the resulting VISA-claudin4–BikDD vector in a panel of breast cancer and normal cell lines confirmed that it strongly inhibited the growth of different breast cancer cell lines, but had little or no effect on the growth of normal human cells. The tumor inhibitory effects of the vector were subsequently confirmed in vivo, in one syngeneic mouse breast tumor and multiple human breast tumor orthotopic xenograft models.

Prior studies had demonstrated that the clinical efficacy of anti-Her2 drugs such as lapatinib and trastuzumab are greatly limited by either inoperative apoptosis machinery or overexpression of Bcl-2 antiapoptotic proteins, the researchers add. With this in mind they moved on to examine whether either the administration of BikDD, or the inhibition of antiapoptotic Bcl-2 proteins could enhance the therapeutic effect of lapatinib in breast cancer cells. They found that VISA-claudin4-BikDD effectively sensitized BT474 and MDA-MB-453 (Her2⁺), and MDA-MB-468 and BT20 (EGFR⁺) cells to lapatinib. Similarly, inhibiting Bcl-2, Bcl-xL, and Mcl-1 using shRNAs also sensitized EGFR⁺/Her2⁺ breast cancer cells to lapatinib, to about the same degree as BikDD vector therapy. Significantly, VISA-claudin4-BikDD therapy in addition sensitized multiple breast cancer cell lines to paclitaxel in vitro.

To further examine the therapeutic efficacy of VISA-claudin4-BikDD plus lapatinib combination in vivo, the researchers then treated mice bearing Her2⁺ BT474 human breast cancer xenografts, with VISA-claudin4-BikDD and/or lapatinib. While VISA-claudin4-BikDD or lapatinib alone had significant tumor inhibitory effects, combining the two treatments demonstrated even better therapeutic efficacy. These results were confirmed in mice carrying tumors derived from different breast cancer cell lines.

To evaluate therapy on BCIC cells in vivo, VISA-claudin4-BikDD, lapatinib, or paclitaxel were either alone or in combination, to treat a MDA-MB-468 tumor orthotopic xenograft mouse model. Consistent with the in vitro data, BikDD treatment significantly reduced the percentage of CD44⁺/CD24^- cells, whereas, as expected, paclitaxel therapy on its own increased this population by about threefold. In fact, combining the two treatments was better at suppressing tumor growth than VISA-claudin3-BikDD therapy alone, even after therapy was withdrawn, the authors note. Similar results were observed as a result of combination therapy with VISAclaudin4-BikDD and lapatinib.

Collectively, these results indicate that BikDD driven by VISA-claudin4 vector potently reduced the CD44⁺/CD24^- population in vivo even after chemotherapy, and efficiently attenuated tumor growth after cessation of drug treatment, suggesting that VISA-claudin4-BikDD treatment may serve as a potential therapeutic approach to kill BCICs, which is considered as a major barrier for breast cancer treatment,” the authors write. “By using our newly developed VISA-claudin4-BikDD for treating breast cancer, it is likely that therapeutic efficacy will be enhanced and potential side effects prevented as we have shown that BikDD targets both non-BCICs and BCICs and demonstrates virtually no toxicity in normal cells…Therefore, it is worthy of moving VISA-claudin4-BikDD into a clinical trial.”

Source: http://www.genengnews.com/gen-news-highlights/scientists-use-mutant-protein-to-inhibit-cancer-stem-cells-and-resensitize-tumors-to-lapatinib/81245670/

Posted under Cell Analysis, Clinical Trials, Discoveries, Innovations and Patents, R & D, Research Projects, Stem Cell Research | Comments Off

Ark to Manufacture PsiOxus’ IV-Administered Oncolytic Virus for Clinical Trials

Last Updated on Monday, 12 September 2011 04:06 Written by admin Monday, 12 September 2011 04:06

Ark Therapeutics negotiated a manufacturing partnership with PsiOxus Therapeutics for the latter’s ColoAd1 candidate for the treatment of colorectal cancer. Under terms of the agreement Ark will work with PsiOxus to generate an IV formulation of the adenovirus-based oncolytic product using its suspension-based single-use system (ATOSUS) for toxicological and Phase I/II clinical studies.

ColoAd1 is an Ad3/Ad11p hybrid, designed as a broad-spectrum anticancer therapeutic capable of destroying tumor cells at minute concentrations, but with minimal damage to healthy tissue. The oncolytic virus has been generated using the evolutionary principle of natural selection, to generate a candidate that PsiOxus claims demonstrates anticancer potency at 0.1–10 femtomolar concentration, including activity against drug-resistant cancers. The initial target indications for ColoAd1 will be metastatic colorectal cancer and primary hepatic cellular carcinoma.

The evolutionary approach used to generate ColoAd1 involves generating a chimeric adenovirus library by homologous recombination under atypical conditions of super-infection, PsiOxus explains. Multiple rounds of selection are subsequently carried out to identify strains with a tumor-dependent phenotype that also rapidly killed tumor cells. Candidate oncolytic viruses are then screened on normal cells to select a candidate with optimal therapeutic index.

PsiOxus was established in December 2010 through the merger of Myotec Therapeutics and Hybrid BioSystems. The ColoAd1 candidate originated at Hybrid Biosystems, a firm initially established to exploit viruses as therapeutics. The candidate was developed by Hybrid in collaboration with Bayer Schering. Hybrid Biosystems also developed the PolyStar vaccine vector system, and PolyMap adjuvant/immunotherapeutics platform, both of which PsiOxus inherited when it was formed last year.

PsiOxus’ lead clinical-stage compound, MT-102, is a small-molecule anabolic catabolic transforming agent, which is currently undergoing a placebo-controlled Phase II trial as a treatment for disease-related cachexia. MT-102 was originally developed by Myotec, itself an Imperial College London spin-out established to progress work by university scientists on the underlying mechanisms of cachexia. PsiOxus says promising preclinical results from in vivo studies evaluating MT-102 against age-related sarcopenia will also be followed up through future clinical studies.

Source: http://www.genengnews.com/gen-news-highlights/ark-to-manufacture-psioxus-iv-administered-oncolytic-virus-for-clinical-trials/81245663/

Posted under Cell Analysis, Clinical Trials, Discoveries, Innovations and Patents, DNA Reasearch, Drug Development, Genetics & Pharmacogenetics, R & D, Reports, Research Projects | Comments Off

Experimental Type 1 diabetes vaccine fails during second step of trial

Last Updated on Monday, 27 June 2011 11:07 Written by admin Monday, 27 June 2011 11:07

The quest for a vaccine to stop Type 1 diabetes in its tracks has hit a roadblock.

An experimental drug failed in the second step of a three-phase trial on 145 American and Canadian patients who had just been diagnosed with the disease.

The vaccine is based on an enzyme that is targeted by a diabetes patient’s immune system.

Researchers hoped the vaccine would train the immune system to not attack the enzyme – a process that destroys the pancreas’ insulin-producing cells.

But according to a study published by the medical journal The Lancet on Monday, patients who got the vaccine experienced no difference in the progression of the disease.

The vaccine was aimed at Type 1 diabetes, which used to be known as juvenile diabetes and affects less than 10% of people with the disease.

Most sufferers have what’s known as adult-onset or Type 2 diabetes.

New research shows vitamin D may ward off those at risk for Type 2 from actually developing the disease.

A study released over the weekend revealed that patients with the high levels of the vitamin were 25% less likely than those with the lowest amounts to get diabetes.

Scientists theorize that vitamin D may help the body produce more insulin or increase the body’s sensitivity to insulin.

Source: http://www.nydailynews.com/lifestyle/health/2011/06/27/2011-06-27_experimental_type_1_diabetes_vaccine_fails_during_second_step_of_trial.html?r=news/national

Posted under Clinical Trials, Discoveries, Innovations and Patents, Drug Development, New Products, North America, R & D, Reports, USA and Canada | Comments Off

Iona Chemistry Professor Researches Cure For ALZ

Last Updated on Monday, 20 December 2010 03:17 Written by Editor Monday, 20 December 2010 03:17

New Rochelle, NY – Do curry spice, wine and apple skins hold the answer for finding a cure for Alzheimer’s disease, Parkinson’s disease and other neurological disorders?

The results of a laboratory research project, recently published in the Journal of Neurochemistry, show that a chemical compound derived from these natural products may be used in neutralizing the toxic effects of chemicals associated with some debilitating and life-threatening neurological diseases.

The findings are the result of a four-year study undertaken by Terrence Gavin, Ph.D., a chemistry professor at Iona College and Richard M. LoPachin, Ph.D, a neurochemist and director of research in the Department of Anesthesiology at Montefiore Medical Center and the Albert Einstein College of Medicine.

In lab experiments it was found that the compound, called 2-ACP, completely protects nerve cells from the harmful effects of type-2 alkenes. There is growing evidence that exposure to type 2-alkenes, which are found in the smoke inhaled from cigarettes, the exhaust of automobiles and even in French fried potatoes, can increase the chances of developing Alzheimer’s and otherneurological conditions. In addition, studies
have shown type-2 alkenes are being produced within the nerve endings during the disease process that presumably initiates Alzheimer’s.

Dr. Gavin said: “The research Dr. LoPachin and I undertook is promising because chemical compounds extracted from curry spice, red wine and apple skins, which are widely used natural products, have already been clinically demonstrated to have neuroprotective properties. This suggests it would be safe and effective to treat humans with the 2-ACP compound.”

He added: “But, these molecular findings worked in laboratory cultures. We now need to confirm the effects of 2-ACP in animal studies. That will be the focus of our efforts in the coming months.”

In addition, Dr. Gavin and some of his students
at Iona will be looking for new compounds that will be as good or better than 2-ACP in combating the effects of type 2-alkenes. “Our goal is to have new compounds ready for testing in six months. This is a very exciting scientific exploration,” Dr. Gavin stated.

Dr. Gavin has been a chemistry professor at Iona since 1982. He holds a doctoral degree in chemistry from the State University of New York at Stony Brook and attended the State University of New York at New Paltz where he earned a B.A. degree. He and his family live in New Paltz.

Source: westchester.com

Posted under Alzheimer's disease, Clinical Trials, Discoveries, Innovations and Patents, Drug Development, Medicinal Chemistry, Natural Products, North America, Reports, Research Projects, USA and Canada | Comments Off

Novel ‘Antisense’ Therapies Protect Primates from Lethal Ebola and Marburg Viruses

Last Updated on Monday, 30 August 2010 02:01 Written by Editor Monday, 30 August 2010 02:01

ScienceDaily (Aug. 23, 2010) — New studies show that treatments targeting specific viral genes protected monkeys infected with deadly Ebola or Marburg viruses. Furthermore, the animals were protected even when therapeutics were administered one hour after exposure — suggesting the approach holds promise for treating accidental infections in laboratory or hospital settings.
See Also:
Health & Medicine

* Viruses
* HIV and AIDS
* Infectious Diseases

Plants & Animals

* Virology
* Microbes and More
* Monkeys

Reference

* Ebola
* Tropical disease
* Antiviral drug
* Human parainfluenza viruses

The research, which appears in the August 22 online edition of the journal Nature Medicine, was conducted by the U.S. Army Medical Research Institute of Infectious Diseases in collaboration with AVI BioPharma, a Washington-based biotechnology firm.

Working with a class of compounds known as antisense phosphorodiamidate morpholino oligomers, or PMOs, scientists first performed a series of studies with mouse and guinea pig models of Ebola to screen various chemical variations. They arrived at a therapy known as AVI-6002, which demonstrated a survival rate of better than 90 percent in animals treated either pre- or post-exposure.

Encouraged by these results, the team conducted “proof of concept” studies in which 9 rhesus monkeys were challenged with lethal Ebola virus. Treatment was initiated 30-60 minutes after exposure to the virus. In these studies, 5 of 8 monkeys survived, while the remaining animal was untreated. Further experiments, including a multiple-dose evaluation, also yielded promising results, with 3 of 5 monkeys surviving in each of the AVI-6002 treatment groups when they received a dose of 40 mg per kg of body weight.

According to first author Travis K. Warren of USAMRIID, antisense drugs are useful against viral diseases because they are designed to enter cells and eliminate viruses by preventing their replication. The drugs act by blocking critical viral genetic sequences, essentially giving the infected host time to mount an immune response and clear the virus.

Ebola and Marburg cause hemorrhagic fever with case fatality rates as high as 90 percent in humans. The viruses, which are infectious by aerosol (although more commonly spread through blood and bodily fluids of infected patients), are of concern both as global health threats and as potential agents of biological warfare or terrorism. Currently there are no available vaccines or therapies. Research on both viruses is conducted in Biosafety Level 4, or maximum containment, laboratories, where investigators wear positive-pressure “space suits” and breathe filtered air as they work.

The USAMRIID team next turned its attention to Marburg virus, again screening various compounds in mice and guinea pigs to select a candidate for further testing. They settled upon AVI-6003, a drug that consistently conferred a high degree of efficacy (better than 90 percent survival) in both models.

Investigators conducted two pilot studies in cynomolgus monkeys to assess the efficacy of AVI-6003 against lethal challenge with Marburg virus. As with the Ebola studies, treatments were initiated 30-60 minutes after infection. All 13 animals receiving AVI-6003 survived. Additional research provided important information about the optimal therapeutic dose range of the compound, with a 40 mg per kg body weight dose protecting 100 percent of the monkeys following challenge.

“This report of successful early post-exposure treatment of filovirus hemorrhagic fever is significant on its own,” said Colonel John P. Skvorak, USAMRIID commander, “but the drug characteristics of these PMOs also support investigation of potentially broader therapeutic applications.”

Senior author Sina Bavari said USAMRIID has been collaborating with AVI BioPharma since 2004. In February of that year, an Institute scientist working in a Biosafety Level 4 laboratory stuck her thumb with a needle while treating Ebola-infected mice with antibodies. As a precaution, USAMRIID medical experts recommended the investigator be isolated for 21 days to ensure that she had not been infected.

Coincidentally, earlier that very day, Dr. Patrick Iversen from AVI BioPharma had presented a seminar at USAMRIID concerning the efficacy of novel antisense drugs against a range of viruses. When he found out that a USAMRIID scientist had potentially been exposed to Ebola virus, the company volunteered to design and synthesize compounds against the virus to treat her if the need arose.

The team at AVI worked for four straight days to generate human-grade anti-Ebola compounds. In the meantime, their regulatory staff worked with USAMRIID physicians to gain emergency approval from the U.S. Food and Drug Administration to use the compounds if necessary. Five days after the exposure, AVI delivered the compounds to USAMRIID’s medical team.

Fortunately, the scientist had escaped infection with Ebola virus, so the compounds were never used. However, USAMRIID went on to test them in animal models, and has been collaborating with AVI ever since.

According to the authors, the investigational new drug applications (IND) for AVI-6002 and AVI-6003 have been submitted to the U.S. Food and Drug Administration, and they are now open to proceed with clinical trials.

Collaborating on the study were Travis K. Warren, Jay Wells, Kelly S. Donner, Sean A. Van Tongeren, Nicole L. Garza, Donald K. Nichols, Lian Dong, and Sina Bavari of USAMRIID; Kelly L. Warfield and Dana L. Swenson, formerly of USAMRIID; and Dan V. Mourich, Stacy Crumley, and Patrick L. Iversen of AVI BioPharma.
source: sciencedaily.co

Posted under Clinical Trials, Reports | Comments Off

Nine U.S. Health Research Centers to Receive $255 Million

Last Updated on Tuesday, 27 July 2010 03:01 Written by admin Thursday, 22 July 2010 03:51

Nine health research centers have received funds to develop ways to reduce the time it takes for clinical research to become treatments for patients. The funds were awarded as part of the Clinical and Translational Science Awards (CTSA) program which is led by the National Center for Research Resources (NCRR), part of the National Institutes of Health.

“A critical goal of biomedical research is to transform discoveries into preventions, treatments, and cures,” said NIH Director Francis S. Collins, M.D., Ph.D. By working together, CTSAs are removing barriers to research, training new generations of clinical and laboratory research teams, and providing them with the equipment and resources they need.

Now in its fourth year, the CTSA consortium has generated resources that transform the research and training environment to enhance the efficiency and quality of clinical and translational research. Examples include a Web-based national recruitment registry that connects researchers with volunteers interested in participating in clinical studies, establishing public-private partnerships, and a portal that connects researchers with potential investigational drugs that may be useful in new ways.

The 2010 CTSAs expand consortium representation in new areas including New Mexico, Virginia and the District of Columbia, growing the consortium to 55 member institutions. The nine new institutions are:

Children’s National Medical Center, Washington, D.C.
Georgetown University with Howard University, Washington, D.C.
Medical College of Wisconsin, Milwaukee
University of California, Irvine
University of California, San Diego
University of Massachusetts, Worcester
University of New Mexico Health Sciences Center, Albuquerque
University of Southern California, Los Angeles
Virginia Commonwealth University, Richmond

View descriptions of these CTSA awardees at www.ncrr.nih.gov/ctsa2010.

“The nine institutions that have received CTSAs this year extend the geographic reach of the consortium and bring additional talent and expertise in such areas as children’s health, outreach to underrepresented communities, and systems to share research information,” said NCRR Director Barbara Alving, M.D.

The CTSA consortium now includes awardees in 28 states and the District of Columbia. When the program is fully implemented in 2011, it will support approximately 60 CTSAs across the nation.

A sixth and final funding opportunity announcement for CTSAs is available, calling for the next round of applications to be submitted by Oct. 14, 2010, with the awards expected in July 2011. For more information about this funding announcement, see www.ncrr.nih.gov/crfunding.

For more information about the CTSA program, visit www.ncrr.nih.gov/ctsa. The CTSA consortium website, which provides information on the consortium, current members and new grantees, can be accessed at www.CTSAweb.org.

The National Center for Research Resources (NCRR), a part of NIH, provides laboratory scientists and clinical researchers with the resources and training they need to understand, detect, treat and prevent a wide range of diseases. NCRR supports all aspects of translational and clinical research, connecting researchers, patients and communities across the nation. For more information, visit www.ncrr.nih.gov.

The National Institutes of Health (NIH) The Nation’s Medical Research Agency includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

Posted under Business and Investment, Cancer Research, Clinical Trials, North America, Press Releases, Research Projects | Comments Off

DiscoveryBioMed, Inc. Awarded Phase 2 SBIR Grant by the NIH to Discover Hypertension and Cystic Fibrosis (CF) Drugs

Last Updated on Monday, 12 October 2009 12:50 Written by Editor Monday, 12 October 2009 12:50

BIRMINGHAM, Ala.–(BUSINESS WIRE)–DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a $750,000 Small Business Innovations Research (SBIR) Phase 2 grant by the National Institutes of Health (NIH) to continue the research into the discovery and development of small molecules to alleviate multiple chronic human diseases including cystic fibrosis (CF), hypertension and chronic kidney diseases with hypertension.

â€œWe are proud to have been awarded this grant and to have our technology again recognized and validated by the NIH,â€ said Dr. Erik Schwiebert, Chief Executive Officer of DiscoveryBioMed. â€œWith our academic partners at the University of Alabama at Birmingham and at Johns Hopkins University School of Medicine, we stand ready to test lead compounds for safety and efficacy in both CF and hypertensive animal models.â€

DBM has adapted a known electrical bioassay method to be high-throughput screening friendly, a necessary solution to bring the bioassay to the molecular target endogenous to the apical cell membrane of polarized renal and respiratory epithelia. The molecular target in play for this drug discovery program is an epithelial ion channel that is the rate-limiting step for the handling of salt in the distal portions of the kidney and in the respiratory tract. When over-active, this sodium channel can cause dehydration of the airways and too much salt in the blood, leading to high blood pressure.

â€œTo successfully study this ion channel target, we had to bring the bioassay to the target where it is most comfortable, the apical membrane of a polarized epithelium simulated in in vitro 3D culture,â€ continued Dr. Schwiebert. â€œResearchers refer to this target as ‘twitchy’ since it does not behave the same in other experimental systems. It also depends upon factors produced by the epithelium itself to maintain proper activity. DBM brought the assay to the target and remains true to the principle that the target should be endogenous to a human or mammalian epithelial cell system to empower the most biologically-relevant drug discovery program. We believe screening on life-like human cell platforms is essential in development of drugs that ultimately will be provided to human patients.â€

Additionally, DiscoveryBioMed has a pair of closely related lead compounds in hand that it will use as a medicinal chemistry platform. Additional hit-to-lead compounds are emerging. At the end of Phase 2, DBM anticipates having pre-clinical animal data and, possibly, proof-of-concept efficacy data in animals and in humans to show to potential out-license partners.

About DiscoveryBioMed, Inc.

DiscoveryBioMed, Inc. is a life sciences and biotechnology company that engages in R&D and services work in cell engineering and production and cell-based drug discovery. The company is located within The Innovation Depot facility in Birmingham, Alabama. Using physiologically relevant cell culture models preferably derived from normal and diseased adult human cells and tissues, DBM focuses on finding therapeutic compounds for a variety of human diseases. It also applies this custom human cell-based approach to its â€œfee-for-serviceâ€ support to researchers in allied areas and currently serves clients both locally in Alabama as well as in 11 other states in the US currently. For more information, visit the DBM website at www.discoverybiomed.com.

Source: Businesswire.com

Posted under Business and Investment, Clinical Trials, Collaborations, Compound Screening, Press Releases | Comments Off

Clinical Trials in Asia Summit 2009

Last Updated on Sunday, 10 May 2009 09:20 Written by admin Sunday, 10 May 2009 09:20

Determining the prospective strategies for Implementing Clinical trials in India & South Asia – Today’s Hottest Market

18th – 20th May 2009, The Park, New Delhi, India

Â

Key Speakers
â€¢ Chandrashekhar Potkar, Director, Medical and Regulatory Affairs, Pfizer, India
â€¢ Viraj Rajadhyaksha, Senior Manager, Operations, Planning & Mgmt Clinical Research, Pfizer, India
â€¢ Rajesh Karan, Regional Head of Translational Medicine & Scientific Operations, Novartis, India
â€¢ Anirban Roy Chowdhury, Clinical Research Manager, AstraZeneca, India
â€¢ Subbaraju Sagi, Senior Sales Consultant,Oracle Health Sciences
â€¢ Mark Engel, Chairman, Excel PharmaStudies, China
â€¢ Celestine Juliet, Project Manager, Cipla
â€¢ Krathish Bopanna, Senior Vice President, Acunova
â€¢ Nermeen Varawalla, Vice President, Scientific & Medical Affairs, PRA International, London
â€¢ Paula Mumby, Director, i3 Pharma Resourcing
â€¢ Dan Zhang, CEO, Fountain Medical Development, China
â€¢ Dalvin Ni, VP, Fountain Medical Development, China
â€¢ Milind Antani, Head-Pharma LifeSciences group, Nishith Desai
â€¢ Arun Bhatt, President, Clininvent Research
â€¢ Arani Chatterjee, Vice President,

Â

India has all the competitive advantages for conducting clinical trials. As the country is increasingly becoming a favored destination for clinical trials, a gap analysis needs to be done to scale up all resources for clinical trials. This scale up is essential for India to cope with the large global clinical trial projects. It is no coincidence over the last decade or more of economic liberalization, and years of unprecedented growth, that India and parts of South Asia are becoming a preferred clinical research destination for multinational pharmaceutical and biotechnology corporations.

Clinical Trials Summit 2009 will discuss the on-going pressing concerns faced in clinical trials operations, addressing the risks, timeline and budget constraint, whilst effectively tackling key challenges in overcoming trials agreement and site contract negotiation hurdles. This year, the operational element of trial site management, strategic partnership with CROs and SMOs, patient, talent & investigators management will be discussed in order to improve and optimize the overall drug development effectiveness and ROI. Find out how to implement and benefit from electronic data management & monitoring cost effectively. This event will be shared by leading industrial practitioners across the region to promote practical discussions; especially on the know-how to manage needs, variability of different countries and institutions to enhance clinical operational excellence and vigilance. Delegates will have the opportunity to learn, network and benchmark against the global top pharmas and local industry leaders on the best practices in talent, site, budget and performance management in clinical trials. The conference aims to provide a detailed analysis of what it takes to conduct clinical trials from a biopharmaceuticals and vaccines perspective in India and China and also addressing risk/benefit balance, anecdotal experiences of the multinational pharmaceutical industry in India and China, selection and role of CROs, logistics of operations, clinical trials management, government policies (including IPR issues) and pharmacovigilance.

Reasons to register today:
â€¢ How can you take advantage of the global market for clinical trials?
â€¢ Improving and optimizing site management and overall productivity of clinical operations
â€¢ Optimising clinical trials operation effectiveness and ROI through strategic site, patient, data and risk management in the regulated markets
â€¢ Identify the data management, CMC supply chain, operational requirements and CRO infrastructure in India and South Asia
â€¢ Gaining insights on future forwards of clinical trials and valuing its potential
â€¢ Discover how to improve your supplier-client relationships
â€¢ Complete trials on schedule and budget by learning to overcome hurdles in investigator/patient recruitment
â€¢ What are the issues with off-shoring trials to countries such as India & South Asia? What are the ways to overcome them?
â€¢ Explore innovative strategies for outsourcing, what you should be looking for in a CRO?
â€¢ Working with limited budget to ensure on time study completion
â€¢ Escalating patient recruitment and improving patient retention to save cost and reduce lead-time
â€¢ Maximizing trials results through overseas multinational/multi-centric trials
â€¢ Avoiding potential pitfalls of trials agreement
â€¢ Motivating and managing clinical project teams to improve timeline and progressÂ

Who should attend?
From pharmaceutical, biotech and CROâ€™s: Directors and Heads of:
â€¢ Clinical Research & Development
â€¢ Clinical Research Services
â€¢ Clinical Operations
â€¢ Clinical Data Management
â€¢ Clinical IT
â€¢ Clinical Trials
â€¢ Medical Affairs
â€¢ Regulatory Affairs
â€¢ Compliance
â€¢ Quality Control/Assurance/GCP
â€¢ Clinical Study Design
â€¢ Safety Surveillance
â€¢ Subject Recruitment
â€¢ E-Clinical Systems

Location
The Park, New Delhi
15 Parliament Street, New Delhi, 110001
Tel: +91 011 2374 3000 Ext 1902, Fax: +91 11 233629320

www.visiongain.com

Posted under Asia, Asia, Clinical Trials, Press Releases | Comments Off

Plexxikon Receives Key Patents on Novel Compounds for Multiple Programs

Last Updated on Friday, 27 March 2009 10:00 Written by admin Friday, 27 March 2009 10:00

BERKELEY, Calif.–(BUSINESS WIRE)–Plexxikon Inc. today announced the issuance of key composition-of-matter patents covering novel compounds discovered through the companyâ€™s Scaffold-Based Drug Discoveryâ„¢ platform. Plexxikonâ€™s pipeline of preclinical and clinical stage product opportunities currently span potential treatments for cardio-renal disease, CNS disorders, inflammation, metabolic disease and oncology. Two of the three recently issued patents (U.S. patents no. 7,498,342 and no. 7,504,509) cover compounds derived from the companyâ€™s discovery efforts to target protein kinases for the treatment of multiple indications including oncology and inflammation. The third patent (U.S. patent no. 7,476,746) covers novel compounds from the companyâ€™s PPAR (peroxisome proliferator-activated receptor) program yielding novel therapeutic opportunities for metabolic disorders and other diseases.

â€œWe are pleased to be adding these additional patents to our growing and broad intellectual property portfolio,â€ stated K. Peter Hirth, Ph.D., chief executive officer of Plexxikon. â€œPlexxikonâ€™s novel approach to drug discovery has enabled the company to advance multiple first-in-class drug candidates which are covered by strong intellectual property, and as a result, to secure significant pharmaceutical industry interest in our programs.â€

In contrast to fragment-based approaches, Plexxikonâ€™s platform has generated multiple product opportunities by mining the relatively unexplored chemical space of scaffold-like cores and by utilizing co-crystallography early in the discovery process to guide chemical optimization of these scaffolds. Further, the company has developed methods to make highly selective kinase inhibitors as yet rarely seen. Plexxikon has demonstrated the ability to develop selectivity between two targets with as little as one amino acid difference in their catalytic domains. This capability has created the opportunity for the development of new targeted drugs not only for oncology, but also for chronic disease indications outside oncology where safety hurdles are even higher. To date, Plexxikonâ€™s platform has led to the development of a targeted medicine for the treatment of melanoma, a drug candidate for polycystic kidney disease (PKD), an oral agent for rheumatoid arthritis and a broad spectrum oral diabetic therapeutic, all representing novel agents addressing significant unmet needs.

Dr. Prabha Ibrahim Promoted to Vice President of Chemistry

In other news, Prabha N. Ibrahim, Ph.D., was promoted to the position of vice president of chemistry, bringing over 15 years of experience to her position. As head of chemistry since 2002, she has played a key role in building the companyâ€™s synthetic and medicinal chemistry capabilities leading to the discovery of Plexxikonâ€™s novel drug candidates now in the clinic and in preclinical development. Prior to Plexxikon, Dr. Ibrahim was a senior scientist at CV Therapeutics, where she was responsible for the identification and development of preclinical candidates for cardiovascular indications. She also previously worked at Amgen, where she played an integral role in small molecule drug discovery for inflammation therapeutics. Dr. Ibrahim earned her Ph.D. at the University of Victoria, Canada, and was a Welch Foundation Fellow at Rice University in Houston.

Plexxikon Profile

Plexxikon is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. The companyâ€™s clinical stage programs include PLX4032 for the treatment of melanoma and colorectal cancer, PLX5568 for the treatment of PKD and PLX204 for the treatment of diabetes. Among the companyâ€™s preclinical development programs, candidates are being developed for the treatment of rheumatoid arthritis, multiple sclerosis and other autoimmune diseases.

Plexxikonâ€™s proprietary Scaffold-Based Drug Discoveryâ„¢ platform is being applied to build a pipeline of product opportunities in multiple therapeutic areas. This discovery process integrates multiple state-of-the-art technologies, including structural screening as one key component that provides a significant competitive advantage over other drug discovery approaches. To date, the company has discovered a portfolio of clinical and preclinical stage compounds in varied disease areas addressing significant unmet needs in each therapeutic category.

Plexxikon is seeking pharmaceutical and biotechnology partners for select collaboration opportunities. For more information, please visit www.plexxikon.com.

Posted under ChemInformatics, Clinical Trials, Compound Libraries, Discoveries, Innovations and Patents, Drug-Like Compounds, North America, Press Releases, Targeted Libraries | Comments Off

GTCbio Announces 4th Annual Assay Development and Screening Conference taking place June 8-9, 2009.

Last Updated on Friday, 27 March 2009 09:40 Written by admin Friday, 27 March 2009 09:40

San Francisco, CA – GTCbio Announces its 4th Annual Assay Development and Screening Conference taking place June 8-9, 2009. As compounds derived from high throughput screening increasingly find their way into clinical trials, drug screening has become widely accepted as a critical step in the drug discovery process. After more than a decade of rapid growth, tremendous progress has been made in assay technology, laboratory automation, and informatics. These technological developments have not only facilitated a drastic increase in throughput and efficiency in drug screening, but have also provided novel solutions in other areas of drug discovery and development. As screening has also become prominent in biological research, screening facilities have become increasingly popular in academic institutions.

As the pharmaceutical industry continues to face the challenges of developing more new chemical entities and reducing the cost of R&D, the demand for novel technologies and creative approaches for improving the efficiency of screening has intensified. Cell-based assays used in compound screening and high-content screening technologies have gained popularity in the industry. Years of intensive research have finally resulted in label-free technologies in the drug screening market place. These technologies provide new ways of interrogating cellular and molecular binding events and enable orthogonal screening approaches to drug targets.

The goal of the 4th annual Assay and Screening Technologies Conference is to provide a forum for academics and professionals in the drug discovery industry to stay abreast of exciting new developments in assay technologies while exchanging ideas and developing more efficient approaches to the drug discovery and development process.

For more information, visit http://gtcbio.com/conferenceDetails.aspx?id=123

Posted under Clinical Trials, Compound Screening, Drug Development, HT Screening, North America, Press Releases, USA and Canada | Comments Off

EPA Presents Initial Results from Caliper Life Sciences’ ToxCast Screening Effort

Last Updated on Friday, 20 March 2009 04:59 Written by Editor Friday, 20 March 2009 04:59

HOPKINTON, Mass., March 19 /PRNewswire-FirstCall/ — Caliper Life Sciences, Inc. (NASDAQ: CALP) , a leading provider of tools and services for drug discovery and life sciences research, today announced that the United States Environmental Protection Agency (EPA) presented initial analyses of Phase I data generated by Caliper Discovery Alliances and Services (CDAS) under the EPA’s ToxCast(TM) screening program at the annual meeting of the Society of Toxicology (SOT) held this week in Baltimore, MD. Separately, the EPA notified Caliper that it has exercised the first additional option year under Caliper’s ToxCast contract with the EPA. Task orders under this contract have already generated approximately $3.5 million in total revenues for Caliper since the initiation of the contract in April, 2007, $1.2 million of which was recognized in 2008.

“We are pleased with the preliminary findings presented by the EPA,” said Kevin Hrusovsky, President and CEO of Caliper Life Sciences. “These results, coupled with the EPA’s third year option exercise, reinforce the likelihood for Phase II efforts to begin at Caliper in the third quarter of this year, which supports our expectation of receiving approximately $3 million of service task orders under this contract in 2009.”

Caliper works with the EPA under its ToxCast initiative to develop new in vitro (laboratory) approaches to identify chemicals that are potentially toxic to the environment. The initial phase of the EPA ToxCast program was aimed at creating a database of in vitro assay data on a broad set of compounds for which in vivo (animal) safety data already existed. Key goals for this phase were to assess overall data quality and establish that the database was predictive of in vivo toxicity profiles. Initial analyses of the data generated at CDAS indicate that the goals for high quality data and potential predictive power have been met. For the 11 replicate controls included in the initial 320 compound set, there was greater than 99% concordance in the screening results across 240 assays tested, and more than 200 correlations between the in vitro results generated at CDAS and in vivo toxicity parameters have already been identified. In addition, 75% of the assays tested showed activity for one or more compounds, reinforcing the need for broad in vitro profiling.

“We believe this data presentation validates the importance of in vitro profiling as a tool for predicting potential toxicity liabilities of compounds and highlights the high quality data generated by Caliper,” said David Manyak, Ph.D., Executive Vice President of Discovery Services at Caliper Life Sciences. “Our access to the entire Phase I ToxCast database makes Caliper an ideal partner for collaborative data mining projects. We also believe that the assay screening panel employed by Caliper for the ToxCast initiative will be broadly applicable for product development programs within the agricultural chemical and pharmaceutical industries.”

The ultimate goal of the ToxCast program is to develop a set of predictive in vitro assays that can supplement or replace in vivo tests currently used for regulatory approval of new environmental chemicals. If successful, the ToxCast initiative will reduce the cost and improve the speed of regulatory approval of new environmental chemicals. More extensive data analysis from the EPA is expected in mid-May of this year.

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper’s portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit www.caliperLS.com.

Posted under Clinical Trials, Compound Libraries, North America, Press Releases | Comments Off

Plexxikon Receives Key Patents on Novel Compounds for Multiple Programs

Last Updated on Friday, 20 March 2009 04:54 Written by Editor Friday, 20 March 2009 04:54

Dr. Prabha Ibrahim Promoted to Vice President of Chemistry

Plexxikon Profile

Plexxikon is seeking pharmaceutical and biotechnology partners for select collaboration opportunities. For more information, please visit www.plexxikon.com.

Posted under Clinical Trials, Compound Screening, Discoveries, Innovations and Patents, Drug-Like Compounds, North America, Press Releases, Targeted Libraries | Comments Off

International symposium “Stem Cell Transplantation in Multiple Sclerosis, October 5th, 2009 Moscow, Russia

Last Updated on Friday, 23 January 2009 11:42 Written by admin Tuesday, 13 January 2009 06:19

International symposium “Stem Cell Transplantation in Multiple Sclerosis: Sharing the Experience” will be heldÂ on October 5th, 2009 inÂ Moscow, Russia. Symposuim Organizers are Pirogov National Medical Surgical Center, National Center for Research and Treatment of Autoimmune Diseases, Russian Cooperative Group for Cellular Therapy, New Jersey Center for Quality of Life and Health Outcomes Research.

The symposium will be the first special meeting fully meant to discuss the state-of-the-art and perspectives of the new and quite promising method of multiple sclerosis treatment – high dose immunosuppressive therapy + autologous hematopoietic stem cell transplantation. It intends to share the newly acquired knowledge in the field, to discuss challenges and perspectives of the method, and to develop collaborative projects. The topics to be covered within the symposium include:
“Â Â Â Regimens of conditioning: Immunoablation or immunosupression?
“Â Â Â Types of transplantation: autologous or allogenic?
“Â Â Â Posttransplant immunological reconstitution
“Â Â Â Side effects
“Â Â Â Outcome measures: clinical, imaging, patient-reported outcomes
“Â Â Â Posttransplant neurorehabilitation
“Â Â Â Long-term follow-up results
“Â Â Â Proposals for cooperative studies

Neurologists, immunologists, transplantologists, hematolosits, specialists in stem cell research are invited to participate in the Symposium.

Key dates:

1 March 2009 -Â Â Deadline for abstract submission
1 April 2009Â Â -Â Â Deadline for early registration

Symposium Organizers Contact Information:

Tel: +7 495 463 4923 or +7 962 710 17 11

Web-site: http://www.stemcellms.ru

Posted under Clinical Trials, Europe, Europe, Medicinal Chemistry, North America, Press Releases | Comments Off

CytRx Unveils Clinical Development Plan for Pipeline Assets

Last Updated on Friday, 12 December 2008 02:47 Written by Editor Friday, 12 December 2008 02:47

Names World-Renowned Cancer Drug Expert Dr. Joseph Rubinfeld as Chief Scientific Advisor

LOS ANGELES–(BUSINESS WIRE)–CytRx Corporation (NASDAQ: CYTR) today unveiled its corporate strategy to focus its internal resources on the clinical development of oncology drug candidates tamibarotene and INNO-206, which the Company believes offer the greatest mix of near-term and medium-term revenue potential among its clinical assets. CytRx will pursue partnerships to advance the clinical development of INNO-406 (bafetinib) and its clinical molecular chaperone portfolio, where it continues to see significant future revenue potential. The Company further intends to use its proprietary high-throughput, high-content drug screening Master Chaperone Regulator Assay (MaCRA) platform to discover additional molecular chaperone drug candidates, including those that may inhibit cancer growth, which will support internal efforts to build an oncology drug franchise or future out-licensing possibilities.

CytRx also announced that Board of Directorsâ€™ member Dr. Joseph Rubinfeld has accepted the additional responsibility of Chief Scientific Advisor, and will consult on all aspects of the Companyâ€™s oncology development programs while serving as an important interface between the Company and investors, clinicians and industry thought leaders. Dr. Rubinfeld brings substantial expertise in oncology and drug development through his distinguished career. Dr. Rubinfeld was employed at Bristol-Myers Company International Division as Vice President and Director of Research and Development. While at Bristol-Myers, Dr. Rubinfeld was instrumental in licensing the original anticancer line of products, including Mitomycin and Bleomycin. Among other accomplishments, he was among the four co-founders of Amgen, Inc., and founded SuperGen, Inc., where he previously served as CEO, President and Chief Scientific Officer. In his career he has been instrumental in the development of several blockbuster cancer drugs including cisplatinum, etoposide, erythropoietin, decibitene and pentostatin, and the antibiotics amoxicillin and cefadroxil.

Steven A. Kriegsman, CytRx President and CEO said, â€œWe feel that our stockholders are best served by a focus on potential therapeutics for cancer. We believe tamibarotene has strong potential as a revenue generator with a high likelihood for rapid U.S. approval as a third-line treatment for acute promyelocytic leukemia (APL). Our view is based on the substantial clinical history of tamibarotene as an approved treatment of relapsed APL, in Japan and the existing special protocol assessment (SPA) in place with the U.S. Food and Drug Administration (FDA) for our ongoing U.S. registration clinical trial. We are accelerating enrollment in this clinical trial, with the expectation of filing an NDA with the FDA as early as 2010. We are also taking steps to move into a Phase 2 clinical trial with INNO-206, our highly promising targetable pro-drug for the commonly prescribed chemotherapeutic doxorubicin. We believe that INNO-206 could be effective in a wide variety of cancers, including small cell lung cancer, sarcoma, breast and ovarian cancer and Non-Hodgkins Lymphoma.

â€œImportantly, we expect that we have ample financial resources with our current cash position and investment in RXi Pharmaceuticals Corporation to support this strategy,â€ according to Mr. Kriegsman. â€œWe have strong oncology expertise within CytRx and are delighted that Dr. Joseph Rubinfeld, our long-time board member who has enjoyed an illustrious career developing cancer drugs, will be taking a leadership role in our oncology programs.â€

Dr. Rubinfeld said, â€œHaving reviewed the extensive data on tamibarotene and INNO-206, I am excited about the potential for these two cancer drug candidates and look forward to working closely with the CytRx management team to advance their clinical development to potential commercialization. I am also encouraged by the Phase 1 data we announced earlier this month with INNO-406, now known as bafetinib, which demonstrated positive, clinical responses in 35% of patients with refractory chronic myeloid leukemia. I believe these results will be instrumental in our search for a partnership for bafetinib.â€

Mr. Kriegsman added, â€œWe also stand behind our view that our orally administered molecular chaperone drug candidates, arimoclomol and iroxanadine, provide enormous potential in addressing large, underserved markets and are convinced that the prudent course to maximize stockholder value in this economic climate is to pursue pharmaceutical partners to share additional development costs for these longer-term programs. We intend to complete our ongoing arimoclomol animal toxicology studies and work aggressively toward lifting the current clinical hold in order to enable this drug candidate to move back into the clinic. At that point, we will seek partners for further development of arimoclomol as a therapeutic treatment for both ALS and stroke recovery. Additionally, iroxanadine has shown significant potential as a therapeutic treatment for diabetic foot ulcers and other diabetic complications, and based on Phase 2 data, we will pursue potential partnerships in cardiovascular conditions.â€

CytRxâ€™s drug portfolio includes the following:

Oncology Drug Candidates:

Tamibarotene: CytRx holds the North American and European rights to tamibarotene, a rationally designed, synthetic retinoid compound designed to potentially avoid toxic side effects of the current first-line APL treatment trans-retinoic acid (ATRA). CytRx is actively enrolling patients in a Phase 2 registration clinical trial, known as STAR-1, with tamibarotene to evaluate its efficacy and safety as a third-line treatment for APL. The registration study is being conducted under a Special Protocol Assessment. The FDA has granted Orphan Drug Designation and Fast Track Designation for the use of tamibarotene in patients with relapsed or refractory APL following treatment with ATRA and arsenic trioxide.

There are currently no approved third-line treatment options for refractory APL patients. CytRx estimates the U.S. market opportunity for tamibarotene in refractory APL at approximately $20 million annually. CytRx scientists are also evaluating clinical strategies for developing tamibarotene as a first-line or second-line APL therapy. The estimated annual market potential in the U.S. and Europe for an expanded label including refractory, maintenance and front-line therapy is $150 million. CytRx also retains an option to expand its licenses for the use of tamibarotene in other cancers including multiple myeloma, myelodysplastic syndrome and certain solid tumors in the U.S., and multiple myeloma, myelodysplastic syndrome and solid tumors, other than hepatocellular carcinoma, in Europe.

INNO-206: This pro-drug derivative of the commonly prescribed chemotherapeutic agent doxorubicin is designed to reduce adverse events by controlling drug release and preferentially targeting the tumor. In a Phase 1 study, INNO-206 was administered in doses at up to six times the standard dosing of doxorubicin without an increase in observed side effects over those historically seen with doxorubicin. Objective clinical responses were seen in patients with sarcoma, breast and lung cancers. The Company plans to evaluate further clinical development of INNO-206 in a wide variety of cancers, including sarcomas, breast and ovarian cancer, and Non-Hodgkins Lymphoma.

INNO-406 (bafetinib): INNO-406 (bafetinib), a potent, orally available, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor, is being evaluated for the treatment of patients with chronic myeloid leukemia (CML) and other leukemias that have a certain mutation called the Philadelphia Chromosome (Ph+) and are intolerant of or resistant to imatinib (Gleevec^Â®) and second-line tyrosine kinase inhibitors (i.e. dasatinib (Sprycel^Â®) and nilotinib (Tasigna^Â®)). In November 2008, CytRx announced that bafetinib demonstrated positive, clinical responses in 35% of patients with CML in Phase 1 clinical testing. The Phase 1 clinical trial was used to determine the optimal dose prior to Phase 2 clinical efficacy testing.

CML is a type of cancer that starts in blood-forming cells of the bone marrow and invades the blood. In 2007, the American Cancer Society estimated that approximately 4,600 new cases of CML were diagnosed in the U.S. and that the number will increase as the population ages. Current estimates are that worldwide CML prevalence will increase by 10,000 patients a year, reaching a population of 110,000 in 2010. The global market will grow to an estimated $5.5 billion by 2012.

Molecular Chaperone Regulation

CytRx is a leader in molecular chaperone regulation technology. The Company currently has two orally administered, clinical-stage, drug candidates and recently discovered a series of additional compounds that may provide a pipeline for additional drug candidates. The Company’s drug candidates are believed to function by regulating a normal cellular protein repair pathway through the activation or inhibition of “molecular chaperones.” Because damaged proteins are thought to play a role in many diseases, activation of molecular chaperones that help to reduce the accumulation of misfolded proteins may have therapeutic efficacy in a broad range of disease states. Similarly, CytRx believes that the inhibition of molecular chaperones that normally help protect cancer cells from toxic misfolded proteins may result in the selective destruction of cancer cells.

Arimoclomol: This molecular chaperone regulator drug candidate is being considered as a treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) and stroke recovery. Arimoclomol has been studied in seven Phase 1 and two Phase 2 clinical trials without any significant adverse events. CytRxâ€™s Phase 2b clinical trial with arimoclomol as a treatment for ALS was placed on clinical hold by the FDA in January 2008, unrelated to any data generated by human studies, and additional preclinical toxicology studies are underway to resolve this issue.
Iroxanadine: CytRx believes that this orally available small molecule compound represents a potentially powerful breakthrough in the treatment of vascular diseases that are caused in part by damage to “vascular endothelium” that lines the inside of blood vessels. CytRx believes that endothelial dysfunction plays a key role in the development of various vascular diseases or their complications including diabetic ulcers, thrombosis, retinopathy, and peripheral artery disease. Preclinical and clinical studies with iroxanadine indicate that it has therapeutic potential for the treatment of cardiovascular atherosclerosis. According to the National Heart, Lung & Blood Institute, atherosclerosis is a leading cause of illness and death in the U.S. and affects approximately 4.6 million people annually.

CytRx San Diego Laboratory: The CytRx San Diego Laboratory is using the Companyâ€™s proprietary Master Chaperone Regulator Assay (MaCRA), a cell image-based screening tool that enables the rapid and quantifiable screening of large numbers of small molecule compounds. This technology is used to identify potential drug candidates that modify the activity of a protein known as heat shock transcription factor 1 (Hsf1) and consequently control entire groups of molecular chaperone proteins that repair or degrade toxic misfolded proteins present in diseased cells. Evaluation of the compounds identified in the screen has shown that they exhibit cytoprotective properties in cell culture models of disease. This platform has broad applicability to a range of therapeutic areas, through its ability to identify drug candidates that can either inhibit or amplify molecular chaperone activity. Information related to the development of MaCRA for compound screening was published in the November 2008 issue of the peer-reviewed Journal of Biomolecular Screening.

CytRx Oncology Expertise

Collectively, CytRx’s management and its Board of Directors have brought numerous cancer drugs to market. In addition to Dr. Rubinfeld, the senior managers and directors of CytRx who hold significant oncology experience include: Max Link, Ph.D., Chairman of the Company’s Board of Directors since 1996, who served for a number of years as Chairman and CEO of Sandoz Pharma as well as a director of Alexion Pharmaceuticals, Inc., Celsion Corporation and Discovery Laboratories, Inc.; Jack R. Barber, Ph.D., Chief Scientific Officer, who has significant R&D experience in oncology at Immusol and Viagene, where he most recently served as Head of Oncology; and Shi Chung Ng, Ph.D., Senior Vice President of Research and Development, who has substantial R&D experience at companies such as Abbott and ArQule, Inc., and most recently served as Vice President of Molecular Oncology at Ligand Pharmaceuticals.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The CytRx drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a registration study for the treatment of acute promyelocytic leukemia (APL). CytRx is developing two drug candidates based on its industry-leading molecular chaperone technology, which aims to repair or degrade misfolded proteins associated with disease. The Company owns and operates a research and development facility in San Diego. CytRx also maintains a 45% equity interest in publicly traded RXi Pharmaceuticals, Inc. (NASDAQ: RXII). For more information on the Company, visit www.cytrx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks relating to the outcome or results of any pre-clinical or clinical testing of CytRx’s potential oncology or molecular chaperone drug candidates, including tamibarotene as a third-line treatment for APL, risks related to CytRxâ€™s ability to enter into partnerships to advance the clinical development of INNO-406 and its clinical molecular chaperone portfolio, uncertainties related to the impact of the FDA’s clinical hold on the Company’s arimoclomol clinical trial for ALS on the timing and ability to resume clinical testing at the desired dosage of arimoclomol, the risk that any requirements imposed on the Company’s planned clinical trial designs for ALS or stroke recovery by the FDA as a result of the concerns expressed in their clinical hold of the Company’s ALS program might adversely affect the Company’s ability to demonstrate that arimoclomol is efficacious in treating ALS or stroke patients or cause the Company to cancel one or both of those trials, risks related to CytRx’s need for additional capital or strategic partnerships to fund its ongoing working capital needs and development efforts, risks related to the future market value of CytRx’s investment in RXi and the liquidity of that investment, and the risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx’s most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Posted under Cancer Research, Clinical Trials, Compound Screening, Discoveries, Innovations and Patents, Drug Development, FDA News, Medicinal Chemistry, New Drugs, New Products, North America, Oncology Research, Press Releases, R & D, Research Projects, USA and Canada | Comments Off

MorphoSys and Galapagos Enter Alliance to Co-develop Novel Therapeutic Antibodies in Bone and Joint Disease

Last Updated on Monday, 1 December 2008 12:59 Written by Editor Monday, 1 December 2008 12:59

Combination of Proprietary Drug Targets and Unique Technologies to Create Range of New Therapeutic Antibodies

MUNICH, GERMANY — (Marketwire) — 11/26/08 — MorphoSys AG (FSE: MOR; Prime StandardSegment, TecDAX) and Galapagos NV (Euronext: GLPG) announced today the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis.

The alliance spans all activities from target discovery through to completion of proof of concept clinical trials of novel therapeutic antibodies. Both companies will contribute their core technologies and expertise to the alliance. Galapagos will provide antibody targetsimplicated in bone and joint disease in addition to its adenoviral target discovery platform to discover further targets for antibody development.MorphoSys will contribute its HuCAL antibody technologies to generate fully human antibodies directed against these targets. The initial goal is to further validate the targets through disease-specific in vitro and in vivotesting of the antibodies. After successful validation, the alliance will select antibody programs for pre-clinical and clinical development.Following proof of concept in human clinical trials, programs will be partnered for subsequent development, approval and marketing.

Under the terms of the agreement, Galapagos and MorphoSys will share the research and development costs, as well as all future revenues equally.Decisions will be made by a Joint Steering Committee comprising members of both companies. An initial set of three targets implicated in bone and joint disease has been selected for the collaboration, and Galapagos isalready commencing with production of these proteins for the alliance.Generation of antibodies directed against these targets will start in2009. More targets will be selected using Galapagos’ target discovery platform to fuel the alliance in the coming years. If successful, the first antibody programs based on these novel targets could enter the clinic within four to five years.

“With this alliance, we are adding a biologics strategy to our small molecule drug discovery. Galapagos is the world leader in discovery ofnovel targets, and this alliance with MorphoSys enables us to explore the potential of proprietary antibody targets. Antibody approaches have provento be successful in developing new therapies for major diseases, including rheumatoid arthritis. Having both approaches, small molecules andantibodies, to fill our product pipeline in bone and joint disease willfurther establish Galapagos as the leader in this field,” said Onno van deStolpe, Chief Executive Officer of Galapagos. “With our cash position and revenue streams from both BioFocus DPI and our pharma alliances, we are in a good financial position to enter into this alliance to create value for our shareholders.”

“This alliance represents a major step in our efforts to gain access to novel antibody targets for proprietary drug development in disease areas with a high unmet medical need. The partnership with Galapagos combines both the scientific and financial strength of two leading companies in their space,” said Dr. Simon Moroney, Chief Executive Officer of MorphoSys. “We are excited to combine our broad antibody expertise with Galapagos’ target discovery capabilities and disease know-how to form a successful partnership. The access to novel disease-related target molecules from a renowned partner accelerates the expansion of our proprietary antibody pipeline. This alliance also complements our development efforts in the field of inflammation and arthritis includingour lead program MOR103.”

With this strategic alliance, MorphoSys gains access to a proven target discovery engine as well as to Galapagos’ expertise in bone and joint disease, to support its therapeutic antibody pipeline expansion. The threemain indications of bone and joint disease – rheumatoid arthritis,osteoporosis and osteoarthritis – all represent very significant marketopportunities with several million people affected worldwide and combinedsales of drug treatments of more than US$ 15 billion in 2006.

Through the alliance with MorphoSys, Galapagos enters the rapidly growingmarket for therapeutic antibodies. In 2007, total sales for the 20antibody drugs on the market amounted to more than US$ 25 billion andantibody sales are forecast to increase to approximately US$ 50 billion in 2013. Fully human antibodies are recognized as the next generation and the majority of therapeutic antibodies currently in development are humanized or fully human. The average industry timescale from discovery to pre-clinical development of antibody therapies is only two to three years, considerably shorter than the average six years for small molecules.Antibodies also incur lower attrition rates than small molecules.

Galapagos and MorphoSys will conduct a conference call and live audio webcast today at 02:00 p.m. CET (8:00 a.m EST) to provide detailed information on the alliance.Dial-in number for the Conference Call (listen-only):Germany & U.K. residents: +32 2 401 53 06For U.S. residents: +1 866 931 1567 Please dial in 10 minutes before the beginning of the conference.Approximately two hours after the press conference, the archived webcast will be available for replay of the conference on http://www.morphosys.comand http://www.glpg.com.

For further information please contact: Dr. Claudia Gutjahr-LÃ¶ser, Head ofCorporate Communications & Investor Relations, Tel: +49 (0) 89 / 899 27-122, gutjahr-loeser@morphosys.com or Mario Brkulj, Manager CorporateCommunications & Investor Relations, Tel: +49 (0) 89 / 899 27-454,brkulj@morphosys.com

About Galapagos:

Galapagos (Euronext Brussels: GLPG; Euronext Amsterdam: GLPGA; OTC: GLPYY)is a drug discovery company with pre-clinical programs in bone and jointdiseases and bone metastasis. Its BioFocus DPI division offers a fullsuite of target-to-drug discovery products and services to pharmaceuticaland biotech companies, encompassing target discovery and validation,screening and drug discovery through to delivery of pre-clinicalcandidates. BioFocus DPI also provides adenoviral reagents for rapididentification and validation of novel drug targets, compound libraries fordrug screening as well as chemogenomics and ADMET database products toselect targets and compounds. Galapagos currently employs about 450 peopleand operates facilities in six countries, with global headquarters inMechelen, Belgium. More information about Galapagos and BioFocus DPI canbe found at www.glpg.com and www.biofocusdpi.com.

About Galapagos’ target discovery technology:

Galapagos’ target discovery engine is based on adenoviruses thatefficiently introduce human gene sequences into a wide variety of humancells to knock-down specific proteins. High-throughput assays thatrepresent a selected human disease state are then used to functionallyselect for those proteins that have a causative effect in those models ofhuman disease. After rigorous validation of these protein targets, theyform the basis for the development of novel drugs.

About MorphoSys:

MorphoSys is a publicly traded biotechnology company focused on thegeneration of fully human antibodies as a means to discover and developinnovative antibody-based drugs against life-threatening diseases.MorphoSys’s goal is to establish HuCAL as the technology of choice forantibody generation in research, diagnostics and therapeutic applications.The Company currently has therapeutic and research alliances with themajority of the world’s largest pharmaceutical companies includingBoehringer Ingelheim, Centocor/Johnson & Johnson, Novartis, Pfizer andRoche. Within these partnerships, more than 50 therapeutic antibodyprograms are ongoing in which MorphoSys participates through exclusivelicense and milestones payments as well as royalties on any end products.Additionally, MorphoSys is active in the antibody research market throughits AbD Serotec business unit. The business unit has operations in Germany(Munich), the U.S. (Raleigh, NC) and U.K. (Oxford). For further informationplease visit http://www.morphosys.com/

HuCALÂ® and HuCAL GOLDÂ® are registered trademarks of MorphoSys AG

Posted under Business and Investment, Clinical Trials, Collaborations, Discoveries, Innovations and Patents, Drug Development, Europe, Industry News, Medicinal Chemistry, New Drugs, News by Region, News by Subject, North America, Press Releases | Comments Off

The difficulties of Cushingâ€™s syndrome

Last Updated on Wednesday, 26 November 2008 01:55 Written by Editor Wednesday, 26 November 2008 01:55

Diagnosing and treating Cushingâ€™s syndrome is sometimes just as difficult as it was 70 years ago.

For as long as it has been described, Cushingâ€™s syndrome has presented physicians with a problem. Harvey Cushing first described it in 1932, and the diagnosis, differential diagnosis and treatment of Cushingâ€™s have remained a major challenge for endocrinologists ever since.

Though uncommon, it is difficult to consider Cushingâ€™s syndrome a rare occurrence. New research has shown Cushingâ€™s syndrome to have a substantially higher prevalence than previously thought. Unexpected endogenous hypercortisolism may occur in 0.5% to 1% of patients with hypertension, 2% to 3% with poorly controlled diabetes, 6% to 9% with incidental adrenal masses and 11% with osteoporosis and vertebral fractures.

â€œWe are gaining an appreciation that Cushingâ€™s is more common than it was once believed to be,â€ said Mary Ruppe, MD, endocrinologist at the University of Texas Health Science Center at Houston, and program committee chair of the Women in Endocrinology organization. â€œThis fact points to the need for data regarding the value of the different diagnostic approaches and for data regarding treatment/outcomes in populations with Cushingâ€™s.â€

As most of the characteristics of Cushingâ€™s are common in the general population, including obesity, depression and hypertension, it is extremely difficult for endocrinologists to decide on who should be screened for the disorder. A recent clinical review by Hershel Raff, PhD, and James W. Findling, MD, noted that as the number of patients in these high-risk groups continues to increase, the need for a sensitive and specific diagnostic test for Cushingâ€™s syndrome has become paramount.

The three most commonly performed diagnostic studies for Cushingâ€™s syndrome â€” urine-free cortisol, low-dose dexamethasone suppression test and the nocturnal salivary cortisol â€” are also not without hurdles. All three have been shown to produce false positives and false negatives.

Approximately 80% of patients with Cushingâ€™s syndrome have an adrenocorticotropic-secreting neoplasm from a pituitary tumor (Cushingâ€™s disease) or a nonpituitary neoplasm, and the treatment of Cushingâ€™s disease remains challenging for both endocrinologists and neurosurgeons as well. Transsphenoidal surgery is currently the standard treatment of choice in patients, but achieving surgical remission has been difficult as well.

â€œCushingâ€™s syndrome is a very rare but important diagnosis for the patient and endocrinologist. Confirming the diagnosis may be challenging, and before embarking on a costly set of tests, the endocrinologist should be reasonably assured that the patient indeed requires diagnostic exclusion by rigorous screening methods,â€ said Shlomo Melmed, MD, senior vice president of Academic Affairs at Cedars Sinai Medical Center, Los Angeles, and an Endocrine Today editorial board member

With more than 7.5 decades of research since Dr. Cushingâ€™s discovery, what are the best methods of diagnosis and treatment for Cushingâ€™s syndrome? Endocrine Today talked with leading researchers in the field to uncover the current trends in Cushingâ€™s syndrome treatment.

Screening process

Laurence Katznelson, MD, associate professor of medicine and neurosurgery at Stanford University, and medical director of the pituitary program at Stanford Hospital and Clinics, explained to Endocrine Today the difficulty of deciding who should be screened for Cushingâ€™s syndrome. For instance, although the syndrome is associated with multiple comorbidities, including obesity, hypertension and depression, endocrinologists should be prepared to delve a little deeper into the symptoms to see if they warrant a screening test.

â€œThe presence of Cushingâ€™s syndrome should be considered if these medical conditions are present, though diagnostic testing should be performed only in subjects who have signs favoring Cushingâ€™s, such as demonstration of objective proximal weakness, spontaneous ecchymoses and violaceous striae,â€ Katznelson said.

â€œFor example, central obesity with supraclavicular and dorsicervical fat pads would favor a diagnosis of Cushingâ€™s syndrome, in contrast to the presence of generalized obesity,â€ he said.

Raff and Findling noted in a recent clinical review that endogenous cortisol excess also leads to fairly specific catabolic effects â€” including the thinning of the skin with easy bruising, abdominal striae, poor wound healing, immune suppression, rib fractures, hirsutism in women, acne and muscle wasting leading to proximal muscle weakness.

â€œThere is no clear guideline,â€ said Roberto Salvatori, MD, associate professor of medicine in the division of endocrinology at Johns Hopkins University School of Medicine. â€œYou need to keep your mind open.â€

â€œSometimes Cushingâ€™s is obvious. Sometimes, when it is mild, it may not be diagnosed for many years. One must screen a lot of patients to find one with Cushingâ€™s. However, anytime a physician thinks about the possibility of a patient having the disease, work-up should be initiated,â€ he said.

Testing options

Opinions varied when Endocrine Today asked researchers which of the three tests for Cushingâ€™s syndrome was most reliable.

â€œNo test is 100% sensitive or specific,â€ Salvatori said. â€œI always use two, sometimes three, screening tests.â€ However, Salvatori noted he feels the night-time salivary cortisol test is the most reliable and easy to obtain.

Raff and Findling described the measurement of free cortisol in a 24-hour urine collection as being long considered the gold standard for the diagnosis of endogenous hypercortisolism. The test relies on the concept that as daily production of cortisol is increased, the free cortisol filtered and not reabsorbed or metabolized in the kidneys will be increased. They noted that current research has shown that many patients with mild Cushingâ€™s syndrome do not have elevations of urine-free cortisol, â€œmaking it a poor screening test for this condition.â€

The low-dose dexamethasone suppression test relies on the concept that the correct dose of dexamethasone will suppress ACTH, and cortisol will release in normal patients while patients with corticotroph adenomas will not suppress below a specified cut off. Raff and Findling noted that because of the significant variability of the biological behavior of corticotroph adenomas, research has shown that neither the overnight 1-mg dexamethasone suppression test nor the two-day low-dose dexamethasone suppression test appears to be reliable using the standard cutoffs for serum cortisol.

According to Raff and Findling, there is no diagnostic test used in the evaluation of Cushingâ€™s syndrome that performs better than the late night/midnight salivary cortisol method. The concept is based on the fact that patients with mild Cushingâ€™s syndrome fail to decrease cortisol secretion to its nadir at night. However, they still acknowledged that many factors, such as stress, sleep disturbances and psycho-neuroendocrine may falsely elevate nocturnal cortisol secretion.

â€œBecause each of these tests has associated false positives and negatives, a combination of these tests is often necessary for a valid diagnosis,â€ Katznelson said. â€œIn the end, these tests need to be considered in the context of a history and physical examination that favors this diagnosis.â€

Lynette Nieman, MD, associate director of the Intramural Endocrinology Training Program at the NIH, agreed. â€œOf the three recommended tests, each is useful in certain conditions,â€ she said. â€œI try to stress that the testing should be individualized since some tests are likely to be falsely positive in some situations, eg, a woman on birth control pills is likely to have a high corticosteriod-binding globulin, which might elevate serum cortisol.â€

Ruppe said the choice between the tests should be based on patient characteristics that will allow for adequate collection of each sample. â€œFor instance, the use of a late-night salivary cortisol measurement would be suboptimal in an individual who works the third shift and may not have an intact circadian rhythm, or the choice of a 24-hour urinary free cortisol may be suboptimal in an individual with urinary frequency or urinary incontinence.â€

Ruppe also noted that one possible improvement would be to improve standardization of the assays across different labs. â€œSince there is no standardization, the quality of the performance of the assay can vary across different facilities and centers,â€ she said.

Petrosol sinus sampling

Another controversial topic in the field is whether or not the inferior petrosol sinus should be sampled for an ACTH gradient to distinguish between Cushingâ€™s disease and occult ectopic ACTH syndrome.

The invasive procedure has proven to be relatively safe when performed by experienced radiologists, but not all medical centers have the capability.

A woman with mild hypercortisolism, a normal or slightly elevated plasma ACTH and normokalemia has an approximately 95% likelihood of having Cushingâ€™s disease before any differential diagnostic testing is performed, according to Raff and Findling. In contrast, a male patient with prodigious hypercortisolism of rapid onset, hypokalemia and marked elevations of plasma ACTH may be more likely to have an occult ectopic ACTH-secreting tumor.

About half of patients with ACTH-secreting microadenomas are estimated to have a normal pituitary MRI. In such situations, it is important to perform further testing, particularly an inferior petrosal sinus catheterization, to discern the presence of an ectopic ACTH-producing lesion, according to Katznelson.

â€œSome people would say that every patient should have it because it is the one best test for the differential diagnosis of ACTH-dependent Cushingâ€™s syndrome,â€ Nieman said. â€œHowever, patients in whom data strongly suggest Cushingâ€™s disease might forego it.â€

â€œIn a young woman with an MRI with a definitive adenoma and high-dose dexamethasone test showing less than 60% suppression, it is reasonable to proceed with surgery,â€ Salvatori said. â€œBut even the International Prostate Symptom Score is not 100% sensitive or specific.â€ Raff said that he disagrees with the high-dose dexamethasone test.

Fast Facts: Issues at Hand

Transsphenoidal surgery

Currently, transsphenoidal surgery is the primary treatment of Cushingâ€™s disease associated with an ACTH-secreting pituitary tumor. According to recent studies, remission rates after transsphenoidal pituitary microsurgery range from 42% to 86%.

Raff told Endocrine Today that the most important treatment recommendation that an endocrinologist makes to a patient with Cushingâ€™s disease is referral to a neurosurgeon with extensive experience.

â€œReferral to a neurosurgeon who is highly experienced in this procedure is critical,â€ Katznelson agreed. He noted that there have been studies demonstrating that both the degree of tumor bulk resection and rates of biochemical remission are increased for all types of pituitary tumors when the surgery is performed by a neurosurgeon with extensive experience in endonasal pituitary surgery.

â€œIn Cushingâ€™s disease, this is especially true,â€ Katznelson said. â€œBecause the tumors in this disorder are often small, if not microscopic, the surgical strategy may require dissection through the gland. In inexperienced hands, this may result in higher rates of hypopituitarism and lower rates of biochemical cure,â€ Katznelson said.

â€œThere is no doubt that the surgeonâ€™s experience influences the success rate,â€ Nieman said.

Constantine Stratakis, MD, with the National Institute of Child Health and Human Development, said he agreed, and stressed the importance of confirmation of diagnosis of Cushingâ€™s syndrome prior to a referral to a neurosurgeon.

â€œThere is nothing worse than an inexperienced surgeon operating on a patient with Cushingâ€™s or a surgeon operating on a patient who does not have a firm diagnosis of Cushingâ€™s syndrome,â€ Stratakis said.

â€œSurgery offers a reasonable chance for cure in the hands of an experienced neurosurgeon,â€ said Amir Hamrahian, MD, a staff physician at the Endocrinology Institute at the Cleveland Clinic. â€œWe are currently involved in two studies looking at new medications for medical treatment of patients with Cushingâ€™s syndrome. However, surgery is still the best initial approach for those not cured,â€ Hamrahian said.

The future

â€œMedications are the future for patients with inoperable, recurrent Cushingâ€™s syndrome,â€ Stratakis said, referring to pasireotide (SOM230), a somatostatin analog.

He was part of a study in 2006 examining the in vitro effects of SOM230 on cell proliferation in human corticotroph tumors. Researchers found SOM230 significantly suppressed cell proliferation and ACTH secretion in primary cultures of human corticotroph tumors. They concluded that SOM230 may have a role in the medical therapy of Cushingâ€™s disease. Raff said he believes that clinical trials in patients with Cushingâ€™s disease who used SOM230 were not particularly successful. Anne Klibanski, MD, director of the neuroendocrine clinical center at Massachusetts General Hospital and primary investigator of the study, commented that in vitro studies play a critical role in assessing novel targeted pituitary tumor therapies. It is only in rigorous clinical trials that the overall efficacy and risks of such therapies can be established, she suggested.

Constantine Stratakis, MD

â€œMicrosurgical improvements will also be significant, but the major problem right now is the number of patients who are left untreated with recurrent disease,â€ Stratakis said. â€œFor them, there are very few options other than irradiation, so innovative medical treatments with molecularly designed compounds or targeted to specific receptors and/or functions of the pituitary are the most important advances that I see coming in the near future,â€ Stratakis said.

According to James Liu, MD, assistant professor of neurologic surgery at Northwestern University Feinberg School of Medicine in Evanston, Ill., the future appears bright in the battle against Cushingâ€™s.

â€œTechnical advances in surgery including endoscopic pituitary surgery and pseudocapsular dissection can improve surgical outcomes,â€ Liu said.

Katznelson said he hopes the future will bring improved diagnostic strategies important for detecting true Cushingâ€™s syndrome in the presence of multiple comorbidities. He noted that the ongoing research studies involving innovative medical therapeutic strategies that target the corticotroph adenoma itself, or block the effects of cortisol in the periphery, should bring new treatment options in the future.

â€œThese studies will hopefully lead to novel medical options for this syndrome,â€ Katznelson said. â€œThere have been significant advances in surgery, particularly with the development of minimally invasive, endoscopic surgery that has resulted in both improved biochemical outcomes and patient tolerability.â€ â€“ by Angelo Milone

For more information:

* Aron DC, Raff H, Findling JW. Effectiveness vs. efficacy: the limited value in clinical practice of high-dose dexamethasone suppression testing in the differential diagnosis of ACTH-dependent Cushingâ€™s syndrome. J Clin Endocrinol Metab. 1997:82;1780-1785.

* Batista DL, Zhang X, Gejman R, et al. The effects of SOM230 on cell proliferation and ACTH secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab.2006;91:4482-4488.

* Carroll T, Raff H, Findling JW. Late-night salivary cortisol measurement in the diagnosis of Cushingâ€™s syndrome. Nat Clin Pract Endocrinol Metab. 2008;4:344-350.

* Findling JW, Raff H. Cushingâ€™s syndrome: Important issues in diagnosis and management. J Clin Endocrinol Metab. 2006;91:3746-3753

* Liu JK, Fleseriu M, Delashaw Jr. JB, et al. Treatment options for Cushingâ€™s disease after unsuccessful transsphenoidal surgery. Neurosurg Focus. 2007;23:E8.

* Nieman L. The dexamethasone-suppresssed corticotropin-releasing hormone test for the diagnosis of Cushingâ€™s syndrome: What have we learned in 14 years? J Clin Endocrinol Metab. 2007;92:2876-2878.

* Lad SP, Patil CG, Laws ER Jr, Katznelson L. The role of inferior petrosal sinus sampling in the diagnostic localization of Cushingâ€™s disease. Neurosurg Focus. 2007:23:E2.g

Posted under Clinical Trials, Cushingâ€™s syndrome, Education, Industry News, Medicinal Chemistry, News by Region, News by Subject, North America, Press Releases, Research Projects | Comments Off

Tepnel Expands Genetic Services Portfolio with Addition of Illumina iScan Rapid Reader

Last Updated on Friday, 24 October 2008 10:36 Written by admin Friday, 24 October 2008 10:36

MANCHESTER, United Kingdom & STAMFORD, Conn.–Tepnel Life Sciences PLC (AIM:
TED) today announced that it has expanded its molecular genetic services
offering through the addition of Illumina’s iScan System, a next-generation
scanner that provides researchers conducting genetic variation studies with
significantly greater throughput and application diversity. This
announcement marks the first anniversary of Tepnel’s new pharmaceutical
services facility and makes Tepnel the first commercial provider of iScan
services within the UK.

Combined with Tepnel’s established range of upstream and downstream genetic
capabilities, the Company now offers a full suite of complementary services
from DNA extraction through to Bioinformatics. Illumina’s iScan platform
supports both human and non-human applications and is capable of generating
up to 225 million genotypes per day.

Tepnel also has a variety of other platforms and techniques for SNP-based
investigations for both human and non-human research and clinical
applications. This breadth of service enables Tepnel to provide a complete
solution from DNA extraction through to SNP genotyping and DNA sequencing,
all undertaken in accordance with Good Laboratory Practice (GLP).

“Tepnel can offer customers a broad portfolio of innovative genetic analysis
assays some of which are supported on our new high-throughput iScan reader,”
said David Scott, General Manager of Tepnel’s Livingston facility. “This new
addition to our service opens up the possibility to our customers of whole
genome association, focused content analysis, copy number variation analysis
and, epigenetics on both human and non-human samples, all within a
regulatory compliant environment.”

“Accelerating and expanding our molecular genetic services at this rapid
pace reflects our commitment to the long-term strategy of building Tepnel’s
market presence in the fast-growing sectors of
pharmacogenomics/pharmacogenetics and genetic disease disposition testing,”
said Allan Brown, Managing Director, Tepnel Research Products & Services.

About Tepnel Life Sciences plc

Tepnel Life Sciences (AIM:TED) is a UK-based international life sciences
products and services Group with two divisions, Molecular Diagnostics and
Research Products & Services. The Company has laboratories, manufacturing
and operations in the USA, UK and France with over 200 employees. Tepnel
provides test kits, reagents and services to two highly synergistic markets,
these being Molecular Diagnostics and Biomedical Research. The Company’s
strategy has been to identify high growth niche opportunities within these
multi-billion pound markets. Tepnel focuses on these niche operations with
internally developed products, patents, expertise and know-how as well as
strategic acquisitions, to develop a leadership position within these
defined market segments. For more information please visit www.tepnel.com.

Posted under BioInformatics, Clinical Trials, DNA Reasearch, Europe, Genetics & Pharmacogenetics, New Products, Press Releases | Comments Off

Seegene/Lab901 brings a New Detection Platform for Multiple Pathogens to European Hospitals

Last Updated on Friday, 18 July 2008 06:41 Written by admin Friday, 18 July 2008 06:41

Rockville, MD, and Edinburgh, Scotland, June 17, 2008:Â Seegene and Lab901 today announced the availability of a novel automated multi-pathogen walk-away detection platform for European hospitals. Based on the Seeplex(R) multiplexing PCR system and ScreenTape(R)Â gel electrophoresis detection system, this new Seeplex/ScreenTape detection platform will be introduced to clinical and research laboratories in 10 countries across Europe beginning this month.

Seegene and Lab901 have agreed to co-market the testing solutions in the European market. The two companies are responding to requests in Europe for a new automated testing technique to perform what is a routine, but not always consistent, test for biological agents in clinics. Hospital centers in The Netherlands, United Kingdom, Spain, Italy, Norway, Greece, Austria, France, Israel and Turkey have started demonstrations of the automated Seeplex/ScreenTape system.

“As active pathogenic surveillance becomes the norm for healthcare regimes worldwide, clinical research and reference labs will be placed under increased pressure to perform. It is essential that these labs gain the tools and systems that enable them to increase the speed and efficiency of pathogen detection,” said Dr. Jong-Yoon Chun, Founder and Chief Executive Officer, Seegene. “The automated Seeplex/ScreenTape system sets a new standard for automated detection ease of use and performance.”Â

“The simplicity, speed and sample traceability of the Seeplex/ScreenTape system is clearly of real value to diagnostic microbiology and virology laboratories,” said Joel Fearnley, Co-founder and Chief Executive Officer of Lab901. â€œThe ScreenTape system optimized for Seeplex multi-pathogen tests will help speed up discovery and diagnostic procedures.”

The automated Seeplex/ScreenTape tests are based on a Seeplex multiplexing PCR technology from Seegene, which is capable of detecting multiple pathogens in a single tube, and ScreenTape(R),Â an automated walk-away gel electrophoresis detection system from Lab901.

The Seeplex tests with the CE mark and ISO 13485 deliver maximum specificity, reproducibility and sensitivity and can be applied to a broad range of molecular diagnostics, including human, animal, plant and microorganisms. The ScreenTape system will automate the simultaneous analysis of eight or sixteen Seeplex PCR samples. Processing speed for 8 samples is completed within 10 minutes; 16 samples within 18 minutes. ScreenTape displays results using an easy to interpret positive and negative read out. With no gel or buffer preparation and no system priming, even untrained operators can rapidly generate accurate and reproducible test data.

The automated Seeplex/ScreenTape tests are currently available for sexually transmitted diseases (STD), human papillomavirus (HPV), respiratory viruses (RV) and bacterial pneumonia (PB). In addition, further automated Seeplex tests are under development and will be available soon. Particularly, hospitals have showed high interest for the single tube Seeplex Sepsis test scheduled for July release.

About Seegene:

Seegene, Inc. is pioneering the field of multi-pathogen testing. Seegene applies its novel and proprietary Seeplex(R) system utilizing “DPO (Dual Priming Oligo)” and “ACP (Annealing Control Primer)” to create multi-pathogen tests delivering maximum specificity, reproducibility and sensitivity. With over 260 citations and several patents and patents pending, Seegene has been offering advanced molecular diagnostics services to over 1,000 major global institutes in more than 25 countries. Seegene’s mission is to integrate Seeplex(R) with disease diagnostics to provide a new guideline for effectively treating patients. Seegene was founded in 2000 and is based in Rockville, MD and Seoul, Korea. For more information please visit www.seegene.com.

About the Seeplex(R) System: Frontier of Multi-pathogen Detection:

Seeplex(R) is a breakthrough multiplexing PCR technology that enables a new standard in simultaneous multi-pathogen detection. Seeplex(R) works in combination with automatic detection systems such as ScreenTape(R) and delivers a benchmark in testing accuracy, efficiency and cost-effectiveness.

About Lab901:

Lab901 based in Edinburgh, UK, is a leading laboratory automation Company. The D800 ScreenTape(R) for DNA analysis was the first product from a pipeline of consumables that run on the company’s TapeStation(TM) instrument. The new DS12 ScreenTape(R) System, specifically developed for Seeplex(R) tests, automates the analysis of Seegene’s multi-pathogen PCR tests.

About ScreenTape(R) System:

The ScreenTape(R) system is the first automated, walk-away solution for gel electrophoresis. Customers simply load their samples and the ScreenTape(R) into the compact TapeStation(TM) instrument. In just under 10 minutes, fully analysed results for DNA, RNA and protein samples are presented in an easy-to-interpret format.

Posted under Clinical Trials, Collaborations, Europe, HIV Research, New Products, North America, Press Releases | Comments Off

Rentschler Biotechnologie Announces Cooperation with Boehringer Ingelheim

Last Updated on Wednesday, 21 May 2008 01:43 Written by admin Wednesday, 21 May 2008 01:43

Laupheim, Germany, Mai 21, 2008 – Rentschler Biotechnologie and Boehringer Ingelheim, both leading companies in biopharmaceutical development and production, have signed a preferred partnership agreement. The cooperation will enable Rentschler Biotechnologieâ€™s clients to gain access to Boehringer Ingelheimâ€™s large-scale mammalian biopharmaceutical production facilities in Biberach, Germany and vice versa, Boehringer Ingelheimâ€™s clients to use Rentschlerâ€™s facilities of process development and intermediate-scale clinical supply production.

Through the cooperation clients from the pharmaceutical and the biotech industry will benefit from the combined development and manufacturing know-how and facilities, leading to increased flexibility and ultimately more customized services. Compatible bioprocessing methods guarantee a seamless project transfer between the companies which are conveniently located in close vicinity.

Rentschler Biotechnologie, a full-service contract manufacturer focused on process development and small to medium scale production of mammalian cell-derived biopharmaceuticals, currently operates eight independent GMP lines with fermenter volumes of up to 500 L. A 2,500 L has recently been qualified and is going to start operations. Boehringer Ingelheim, who offers similar services with technologies optimized for large scale industrial production, runs one of the worldâ€™s largest biotech facilities with fermenter volumes of up to 15,000 L.

“The cooperation with Boehringer Ingelheim will increase the value of our services, as bothÂ companies will benefit from the combined expertise and the easy transfer from small/medium to large scale productionâ€ commented Dr. Wieland W. Wolf, Vice Chairman of the Rentschler Group.

Prof. Dr. Dr. h.c. Rolf G. Werner, Corporate Senior Vice President of the Corporate Division Biopharmaceuticals,Â Boehringer Ingelheim GmbH saidÂ â€œRentschler Biotechnologie is a strong partner for process development and supply of clinical material in Europe and complements our worldwide strategic Production Alliance Network. Based on compatible process technologies and Boehringer Ingelheims proprietary know-how and expertise in high titer and high yield manufacturing process formats we will combine state-of-the-art development at Rentschler for accelerated time to clinic with a smooth technology transfer to Boehringer Ingelheim for large-scale commercial manufacturingâ€.

Link to the press release:

http://www.b3c.de/php/popup.php?id=103

About Rentschler Biotechnologie â€“ www.rentschler.de

Rentschler Biotechnologie GmbH is part of the privately held Rentschler Group based in Laupheim, Germany. As an international full-service contract manufacturer with a highly skilled staff of 340, Rentschler Biotechnologie has substantial experience in the development, production and approval of cell culture-derived biopharmaceuticals in compliance with international GMP standards. Regulatory advice and fill & finish are part of the company’s service range. As a pioneer in the development and production of biopharmaceuticals, Rentschler was the first company world-wide to gain market authorization for an interferon-containing drug. In 2006, Rentschler announced an investment program of â‚¬50 million for expansion ofÂ production systems. Currently the first 2,500-L GMP fermentation line is being commissioned.

About Boehringer Ingelheim – www.boehringer-ingelheim.com/biopharm

The Boehringer Ingelheim group is one of the worldâ€™s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and nearly 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing innovative products of high therapeutic value for human and veterinary medicine. In 2007, Boehringer Ingelheim posted net sales of almost 11 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development.

Boehringer Ingelheim is one of the leading companies for industrial customer manufacturing of Biopharmaceuticals by offering the entire production technology chain in development and production at its biopharmaceutical facilities in Biberach (Germany) and in Vienna (Austria). The large scale manufacturing sites deliver biopharmaceutical products like therapeutic proteins, fusion proteins, protein scaffolds, monoclonal antibodies, antibody fragments and plasmid DNA. The Biberach site is specialized in highly efficient mammalian cell culture systems with yields well above industry standard in animal component free media. The Austria site offers high-expression in bacteria and yeast with exceptionally high productivities using proprietary systems. In the plasmid DNA manufacturing arena Boehringer Ingelheim in Austria has set the standard and supplies early to late-stage clinical trials with gene-therapeutics and DNA vaccines for its international clients. For more information see: http://www.boehringer-ingelheim.com/biopharm

Rentschler Biotechnologie gibtÂ Zusammenarbeit mit Boehringer Ingelheim bekannt

Laupheim, 21. Mai 2008 â€“ Rentschler Biotechnologie und Boehringer Ingelheim, beidesÂ fÃ¼hrende Unternehmen im Bereich der biopharmazeutischen Entwicklung und Herstellung, haben eine â€žpreferred partnershipâ€œ-Vereinbarung unterschrieben. Durch die Zusammenarbeit erhalten Kunden von Rentschler Biotechnologie Zugang zu Boehringer Ingelheims groÃŸtechnischen Anlagen zur biopharmazeutischen Produktion in SÃ¤ugetierzellen in Biberach. Im Gegenzug erhalten Boehringer Ingelheims Kunden die MÃ¶glichkeit,Â Rentschlers Anlagen fÃ¼r Prozess-Entwicklung und Herstellung von klinischen PrÃ¼fmustern im mittleren MaÃŸstab zu nutzen.

Die Zusammenarbeit ermÃ¶glicht den Kunden aus der Pharma- und Biotech-Industrie die kombinierte Entwicklungs-und Herstellungserfahrung und die Produktionsinfrastruktur beider Unternehmen zu nutzen, Serviceleistungen kÃ¶nnen durch die gewonnene FlexibilitÃ¤t optimal auf KundenwÃ¼nsche abgestimmt werden. Beide Unternehmen liegen in rÃ¤umlicher NÃ¤he zueinander und verfÃ¼gen Ã¼ber kompatible Prozess-Technologien, so dass ein nahtloser Ãœbergang bei Projekttransfers gewÃ¤hrleistet ist.

Rentschler Biotechnologie, ein Full-Service-Auftragshersteller fÃ¼r biopharmazeutische Prozess-Entwicklung und Produktion in SÃ¤ugetierzellen vom kleinen bis mittleren MaÃŸstab, besitzt zurzeit acht unabhÃ¤ngige GMP-Produktionsanlagen mit Fermentervolumina bis zu 500 Litern. Eine weitere 2.500 L Anlage wird derzeit in Betrieb genommen. Boehringer Ingelheim bietet Ã¤hnliche Leistungen und Technologien allerdings fÃ¼r die groÃŸtechnische Marktproduktion und betreibt eine der weltweit grÃ¶ÃŸten Produktionsanlagen mit Fermentervolumina bis zu 15.000 Litern.

â€žDie Zusammenarbeit mit Boehringer Ingelheim wird den Nutzen unserer Dienstleistungen weiter erhÃ¶hen. Beide Unternehmen werden von der gemeinsamen Erfahrung sowie dem leichten Prozess-Transfer von dem kleinen/mittleren MaÃŸstab in den groÃŸen MaÃŸstab profitierenâ€œ, kommentiert Dr. Wieland W. Wolf, Stellvertretender GeschÃ¤ftsfÃ¼hrer der Rentschler Gruppe.

Prof. Dr. Dr. h.c. Rolf G. Werner, Corporate Senior Vice President der Corporate DivisionÂ Biopharmaceuticals, Boehringer Ingelheim GmbH:â€œRentschler Biotechnologie ist ein starker Partner fÃ¼r Prozessentwicklung und Herstellung von klinischem PrÃ¼fmaterial in Europa und ergÃ¤nzt unser weltweites Netzwerk strategischer Produktionsallianzen. Basierend auf kompatiblen Prozesstechnologien und Boehringer Ingelheims geschÃ¼tztem Know-How und Erfahrung in Hochtiterverfahren mit hoher Ausbeute kombinieren wir modernste Prozessentwicklung bei Rentschler fÃ¼r zÃ¼gige Bereitstellung von klinischem PrÃ¼fmaterial mit einem nahtlosen Technologietransfer zur kommerziellen Fertigung im GroÃŸmaÃŸstab bei Boehringer Ingelheim.â€œ

Link zur Pressemitteilung:

http://www.b3c.de/php/popup.php?id=104

Ãœber Rentschler Biotechnologie â€“ www.rentschler.de

Rentschler Biotechnologie GmbH ist ein Unternehmen der Rentschler Gruppe mit Sitz in Laupheim, Deutschland. Als internationales Full-Service-Auftragsunternehmen mit 340 hochqualifizierten Mitarbeitern hat Rentschler Biotechnologie Ã¼ber 30 Jahre Erfahrung mit der Entwicklung, Produktion und Zulassung von Biopharmazeutika, konform mit den internationalen GMP-Standards. Zum Servicespektrum des Unternehmens gehÃ¶ren auch die Zulassungsberatung und Fill & Finish. Rentschler zÃ¤hlt zu den Pionieren bei der Entwicklung und Herstellung von biopharmazeutischen Produkten und war weltweit das erste Unternehmen, das die Zulassung fÃ¼r ein InterferonprÃ¤parat erhalten hat. 2006 gab Rentschler ein Investitionsprogramm von 50 Millionen Euro zur Erweiterung der Produktionsanlagen bekannt. Die erste neue 2.500 L GMP Anlage befindet sich zurzeit in der Qualifizierung (IQ/OQ) und wird im Juni 2008 in Betrieb gehen.

Ãœber Boehringer Ingelheim – www.boehringer-ingelheim.com/biopharm

Der Unternehmensverband Boehringer Ingelheim zÃ¤hlt weltweit zu den 20 fÃ¼hrenden Pharmaunternehmen. Mit Hauptsitz in Ingelheim am Rhein ist Boehringer Ingelheim weltweit mit 135 verbundenen Unternehmen in 47 LÃ¤ndern tÃ¤tig und beschÃ¤ftigt fast 39.800 Mitarbeiter. Schwerpunkte des 1885 gegrÃ¼ndeten Unternehmens in Familienbesitz liegen in der Forschung, Entwicklung, Produktion sowie dem Marketing neuer Arzneimittel mit hohem therapeutischem Nutzen fÃ¼r die Humanmedizin sowie die Tiergesundheit. Im Jahr 2007 erwirtschafte Boehringer Ingelheim GesamterlÃ¶se von 11 Milliarden Euro. Fast ein FÃ¼nftel der Einnahmen aus dem grÃ¶ÃŸten Bereich â€“ verschreibungspflichtige Medikamente â€“ investierte das Unternehmen in die Forschung und Entwicklung neuer Medikamente.

Boehringer Ingelheim ist eines der fÃ¼hrenden Unternehmen in der Auftragsentwicklung und -herstellung von Biopharmazeutika und bietet an seinen Standorten in Biberach/Riss (Deutschland) und Wien (Ã–sterreich) die gesamte biopharmazeutische Prozesskette an â€“ von der Entwicklung der Produktionszelle Ã¼ber die Prozessentwicklung bis zur Herstellung des Marktproduktes im wirtschaftlichen MaÃŸstab. In den Produktionsanlagen werden biopharmazeutische Produkte wie therapeutische Proteine, Fusionsproteine, Protein-Scaffolds, monoklonale AntikÃ¶rper, AntikÃ¶rperfragmente und Plasmid-DNA-Produkte im GroÃŸmaÃŸstab hergestellt. Am Standort Biberach liegt der Schwerpunkt der biopharmazeutischen Herstellung auf der Hochexpression in SÃ¤ugetierzellkulturen mit Ausbeuten weit Ã¼ber dem Branchenstandard in ACF-Medien (ohne tierische Komponenten), am Standort Wien auf der Hochexpression in Mikroorganismen und Hefekulturen mit auÃŸergewÃ¶hnlich hoher ProduktivitÃ¤t unter Einsatz selbst entwickelter Systeme. Auf dem Gebiet der Herstellung von Plasmid-DNA-Produkten setzt Boehringer Ingelheim in Ã–sterreich den weltweiten MaÃŸstab und beliefert sowohl frÃ¼he als auch spÃ¤te klinische Studien fÃ¼r seine internationalen Auftraggeber mit Gentherapeutika und DNA-Impfstoffen.

Weitere Informationen: http://www.boehringer-ingelheim.com/biopharm

Posted under Business and Investment, Clinical Trials, Collaborations, DNA Reasearch, Europe, Press Releases | Comments Off

« Older Entries

Site Search

Archive for the ‘Clinical Trials’ Category

X-Body BioSciences and Tanabe Research Labs Team Up to Develop mAbs for Autoimmune Diseases

Scientists Use Mutant Protein to Inhibit Cancer Stem Cells and Resensitize Tumors to Lapatinib

Ark to Manufacture PsiOxus’ IV-Administered Oncolytic Virus for Clinical Trials

Experimental Type 1 diabetes vaccine fails during second step of trial

Iona Chemistry Professor Researches Cure For ALZ

Novel ‘Antisense’ Therapies Protect Primates from Lethal Ebola and Marburg Viruses

Nine U.S. Health Research Centers to Receive $255 Million

DiscoveryBioMed, Inc. Awarded Phase 2 SBIR Grant by the NIH to Discover Hypertension and Cystic Fibrosis (CF) Drugs

Clinical Trials in Asia Summit 2009

Determining the prospective strategies for Implementing Clinical trials in India & South Asia – Today’s Hottest Market

18th – 20th May 2009, The Park, New Delhi, India

Â

Â

Plexxikon Receives Key Patents on Novel Compounds for Multiple Programs

GTCbio Announces 4th Annual Assay Development and Screening Conference taking place June 8-9, 2009.

EPA Presents Initial Results from Caliper Life Sciences’ ToxCast Screening Effort

Plexxikon Receives Key Patents on Novel Compounds for Multiple Programs

International symposium “Stem Cell Transplantation in Multiple Sclerosis, October 5th, 2009 Moscow, Russia

CytRx Unveils Clinical Development Plan for Pipeline Assets

MorphoSys and Galapagos Enter Alliance to Co-develop Novel Therapeutic Antibodies in Bone and Joint Disease

The difficulties of Cushingâ€™s syndrome

Tepnel Expands Genetic Services Portfolio with Addition of Illumina iScan Rapid Reader

Seegene/Lab901 brings a New Detection Platform for Multiple Pathogens to European Hospitals

Rentschler Biotechnologie Announces Cooperation with Boehringer Ingelheim

Main Menu

Recent Posts

Popular Posts

Last Modified